On May 22, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, reported that it will feature one clinical poster presentation and three online publications at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held June 1-5 in Chicago, IL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ASCO (Free ASCO Whitepaper) Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Bexion’s representation:
Abstract # 2517: First-in-class Phase Ia Study of BXQ-350 for Solid Tumors and Gliomas
Olivier Rixe, MD, PhD, will participate in a Q&A panel presenting data from this study during a Poster Discussion Session on Monday 4 June 2018 from 3:00-4:15 pm. Dr. Rixe’s comments will include that BXQ-350 met its Phase I Safety endpoint with no significant DLT or SAE attributed to drug at the highest planned dose. In addition, it was observed that BXQ-350 showed promising clinical activity in heavily pre-treated patients with recurrent brain cancer and advanced solid tumors.
The following three abstracts will be included online in the 2018 ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings, a Journal of Clinical Oncology supplement, publicly released on May 16, 2018.
Absence of Indicators of Hypercoagulability and Anti-Phospholipid Syndrome in BXQ-350 First in Human Study
Therapeutic BXQ-350 nanovesicles, comprised of a lysosomal activator protein and a phosphor- lipid, did not cause anti-phospholipid syndrome (APS) or clinically significant hypercoagulability in humans.
Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles
Allometric scaling of animal PK/TK data provided reasonable estimates of human PK and exposure for BXQ-350 and can be expected to have good predictive utility for extrapolating drug dose and pharmacokinetic parameters.
Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice
The combination of Gemcitabine and SapC-DOPS demonstrated enhanced antitumor activity in Pancreatic Ductal Adenocarcinoma (PDAC) in mice.
"These abstracts highlight the excitement we have on the potential of BXQ-350 to treat brain and multiple solid tumors; and potentially opening new avenues to treat CNS tumors" stated Dr. Ray Takigiku, Founder and CEO of Bexion.
"The University of New Mexico Comprehensive Cancer Center is pleased to take part in these Phase 1A clinical trials," said Rixe, who is the Principal Investigator at that site and author of the Phase I protocol. "I am honored to present the preliminary results to the scientific community on Bexion’s BXQ-350 and share these exciting new developments."
About BXQ-350
BXQ-350 is a unique formulation of a synthetically produced, human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS).